benefit
(statisticaly significant)
benefit (nominaly significant, not statitically demonstrated) NS not significant harm statitically significant NS harm not significant low certainty due to bias
 
deaths (OS)

mGC or mGEJC - M - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 neg/PDL1 positive

versus Standard of Care (SoC)
avelumab alone vs. Standard of Care (SoC) 1 NS